Sun Pharmaceutical Industries Limited
NSE: SUNPHARMA BSE: SUNPHARMA
Prev Close
1737
Open Price
1712
Volume
3,919,016
Today Low / High
1712 / 1759.9
52 WK Low / High
1548 / 1851.2
Range
1,665 - 1,840
Upper Circuit (5%)
1,840.13
Lower Circuit (5%)
1,664.88
Prev Close
1738.1
Open Price
1703.3
Volume
107,135
Today Low / High
1703.3 / 1758.95
52 WK Low / High
1547.25 / 1850.95
Range
1,665 - 1,840
Upper Circuit (5%)
1,840.34
Lower Circuit (5%)
1,665.07
The stock performance of Sun Pharmaceutical Industries Limited on both the NSE and BSE. On the NSE, the stock is priced at ₹1752.5 (target range: ₹1,665 - ₹1,840), reflecting a slight increase of 0.89%, with a trading volume of 3,919,016 shares. On the BSE, the stock is trading at ₹1752.7 (target range: ₹1,665 - ₹1,840), up by 0.84% with a volume of 107,135 shares. Both exchanges show similar low and high prices, with NSE at ₹1712 - ₹1759.9 and BSE at ₹1703.3 - ₹1758.95 The 52-week range stands at ₹1851.2 - ₹1548 on both exchanges. Both NSE and BSE show positive movement, indicating an upward stock trend—an appealing opportunity for growth-focused investors.
Sun Pharmaceutical Industries Limited Chart
Comprehensive Overview of Sun Pharmaceutical Industries Limited
ISIN
INE044A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,334,600
Market Cap
4,204,834,534,925
Last Dividend
16.5
Range
1548-1851.2
Official Website
IPO Date
1996-01-01
DCF Diff
186.30
DCF
1,504
Latest Dividend Details of Sun Pharmaceutical Industries Limited
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-05 | February 05, 26 | 11 | 11 | 2026-02-05 | 2026-02-16 | |
| 2025-07-07 | July 07, 25 | 5.5 | 5.5 | 2025-07-07 | 2025-08-08 | |
| 2025-02-06 | February 06, 25 | 10.5 | 10.5 | 2025-02-06 | 2025-02-20 | |
| 2024-07-12 | July 12, 24 | 5 | 5 | 2024-07-12 | 2024-08-16 | |
| 2024-02-09 | February 09, 24 | 8.5 | 8.5 | 2024-02-09 | 2024-02-23 |
Comprehensive Annual Financial Performance Report of Sun Pharmaceutical Industries Limited
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 52,578.44 Cr | 11,558.45 Cr | 41,019.99 Cr | 0.7802 | 3,154.19 Cr | 0.00 Cr | 27,814.94 Cr | 10,929.04 Cr | 45.60 | 14,967.94 Cr | 0.2079 |
| 2024-03-31 | 48,496.85 Cr | 11,442.18 Cr | 37,054.67 Cr | 0.7641 | 3,127.70 Cr | 0.00 Cr | 24,424.48 Cr | 9,576.38 Cr | 39.91 | 12,876.00 Cr | 0.1975 |
| 2023-03-31 | 43,885.68 Cr | 11,318.67 Cr | 32,567.01 Cr | 0.7421 | 2,307.72 Cr | 0.00 Cr | 21,904.39 Cr | 8,473.58 Cr | 35.32 | 11,651.32 Cr | 0.1931 |
| 2022-03-31 | 38,654.49 Cr | 10,876.14 Cr | 27,778.35 Cr | 0.7186 | 2,132.51 Cr | 0.00 Cr | 18,291.47 Cr | 3,272.73 Cr | 13.64 | 10,153.57 Cr | 0.0847 |
| 2021-03-31 | 33,498.14 Cr | 9,218.52 Cr | 24,279.62 Cr | 0.7248 | 2,102.82 Cr | 0.00 Cr | 15,272.59 Cr | 2,903.82 Cr | 12.10 | 8,345.11 Cr | 0.0867 |
Essential Financial Ratios Every Investor Must Know of Sun Pharmaceutical Industries Limited
Comprehensive Annual Balance Sheet Overview of Sun Pharmaceutical Industries Limited
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 11,331.62 Cr | 92,100.58 Cr | 19,614.63 Cr | 72,218.0200 Cr | 2,362.19 Cr | -8,969.43 Cr | 10,243.33 Cr | 11,270.28 Cr | 0.00 Cr | 376.74 Cr | 4,697.70 Cr | 18,194.2100 Cr |
| 2024-03-31 | 9,285.65 Cr | 85,462.88 Cr | 18,356.91 Cr | 63,666.7500 Cr | 3,273.67 Cr | -6,011.98 Cr | 10,294.89 Cr | 11,300.05 Cr | 126.54 Cr | 489.37 Cr | 6,441.23 Cr | 16,984.4000 Cr |
| 2023-03-31 | 4,623.73 Cr | 80,743.59 Cr | 21,428.12 Cr | 55,995.3800 Cr | 6,889.66 Cr | 2,265.93 Cr | 10,513.05 Cr | 11,353.73 Cr | 7,256.18 Cr | 569.87 Cr | 5,547.05 Cr | 19,906.3800 Cr |
| 2022-03-31 | 4,508.25 Cr | 69,799.87 Cr | 18,733.76 Cr | 48,011.2200 Cr | 1,290.30 Cr | -3,217.95 Cr | 9,239.16 Cr | 11,168.89 Cr | 11,402.24 Cr | 618.75 Cr | 5,278.68 Cr | 17,200.5500 Cr |
| 2021-03-31 | 6,273.03 Cr | 67,666.73 Cr | 18,186.90 Cr | 46,462.7800 Cr | 3,868.58 Cr | -2,404.45 Cr | 9,361.80 Cr | 11,171.51 Cr | 8,687.82 Cr | 718.55 Cr | 6,482.39 Cr | 16,145.6300 Cr |
Annual Financial Cash Flow Statement Overview of Sun Pharmaceutical Industries Limited
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 14,072.0900 Cr | -5,306.1600 Cr | -7,905.8200 Cr | 11,943.5100 Cr | 983.1200 Cr | 10,268.7700 Cr | -2,128.5800 Cr | 10,929.0400 Cr | -1,030.3400 Cr | -3,613.9700 Cr | -183.9700 Cr |
| 2024-03-31 | 12,134.9800 Cr | -690.2000 Cr | -6,710.1600 Cr | 9,933.1700 Cr | 4,661.9200 Cr | 9,285.6500 Cr | -2,201.8100 Cr | 9,576.3800 Cr | -3,389.9300 Cr | -2,898.1700 Cr | 598.8100 Cr |
| 2023-03-31 | 4,959.3300 Cr | -7,943.6800 Cr | 2,376.0700 Cr | 2,873.7500 Cr | 115.4800 Cr | 4,623.7300 Cr | -2,085.5800 Cr | 9,408.4300 Cr | 5,129.6600 Cr | -2,518.8800 Cr | -1,202.2000 Cr |
| 2022-03-31 | 8,984.5400 Cr | -5,724.7400 Cr | -5,193.4600 Cr | 7,489.5000 Cr | -1,764.7800 Cr | 4,508.2500 Cr | -1,495.0400 Cr | 4,481.3200 Cr | -2,636.7100 Cr | -2,158.9200 Cr | 306.9500 Cr |
| 2021-03-31 | 6,170.3700 Cr | 536.2200 Cr | -5,980.4800 Cr | 5,000.2400 Cr | 596.4200 Cr | 6,273.0300 Cr | -1,170.1300 Cr | 2,799.3700 Cr | -4,489.6400 Cr | -1,559.4700 Cr | -1,080.2900 Cr |
Quarterly Financial Performance Highlights of Sun Pharmaceutical Industries Limited
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 15,520.54 Cr | 6,569.43 Cr | 8,951.11 Cr | 0.5767 | 4,062.24 Cr | 3,368.81 Cr | 14.04 | 5,037.85 Cr | 0.2171 |
| 2025-09-30 | 14,478.31 Cr | 6,477.02 Cr | 8,001.29 Cr | 0.5526 | 3,367.08 Cr | 3,117.95 Cr | 13.00 | 4,996.97 Cr | 0.2154 |
| 2025-06-30 | 13,851.40 Cr | 6,316.97 Cr | 7,534.43 Cr | 0.5439 | 3,372.07 Cr | 2,278.63 Cr | 9.50 | 3,948.12 Cr | 0.1645 |
| 2025-03-31 | 12,958.84 Cr | 3,448.28 Cr | 9,510.56 Cr | 0.7339 | 6,153.90 Cr | 2,149.88 Cr | 9.00 | 3,446.39 Cr | 0.1659 |
| 2024-12-31 | 13,675.46 Cr | 2,740.54 Cr | 10,934.92 Cr | 0.7996 | 7,557.87 Cr | 2,903.38 Cr | 12.10 | 4,150.77 Cr | 0.2123 |
Comprehensive Quarterly Financial Balance Sheet of Sun Pharmaceutical Industries Limited
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 12,257.42 Cr | 15,623.01 Cr | 27,880.43 Cr | 15,447.70 Cr | 10,442.20 Cr | 60,136.43 Cr | 11,761.84 Cr | 103,706.50 Cr | 25,579.91 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 26,122.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -72,485.95 Cr |
| 2025-03-31 | 11,331.62 Cr | 13,656.10 Cr | 24,987.72 Cr | 13,046.11 Cr | 10,243.33 Cr | 52,624.47 Cr | 11,270.28 Cr | 92,100.58 Cr | 19,614.63 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 20,122.19 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -69,379.65 Cr |
| 2024-09-30 | 9,015.00 Cr | 11,107.19 Cr | 20,122.19 Cr | 12,989.39 Cr | 9,935.65 Cr | 46,105.45 Cr | 11,248.33 Cr | 88,115.66 Cr | 18,736.01 Cr |
Quarterly Cash Flow Statement: A Detailed Financial Overview of Sun Pharmaceutical Industries Limited
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 2,278.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 2,149.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 2,903.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 3,040.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 2,835.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Historical Stock Splits Overview of Sun Pharmaceutical Industries Limited
| Date | Label | Split Ratio |
|---|---|---|
| 2013-07-29 | July 29, 13 | 2:1 |
| 2010-11-25 | November 25, 10 | 5:1 |
| 2004-05-27 | May 27, 04 | 2:1 |
| 2003-01-13 | January 13, 03 | 2:1 |
| 2000-03-08 | March 08, 00 | 3:1 |
Executive Profiles of Sun Pharmaceutical Industries Limited
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born: 1958
Gender: male
Year Born: 1984
Gender: male
Year Born:
Gender: male
Year Born: 1971
Gender: male
Year Born: 1955
Gender: male
Year Born: 1954
Gender: male
Year Born: 1967
Gender: male
Year Born:
Gender: female
Year Born: 1968
Frequently Asked Questions about Sun Pharmaceutical Industries Limited
The CEO of the company is Dilip Shantilal Shanghvi.
The current trading price of the stock is ₹1,752.50.
The 52-week price range of this stock is ₹1548-1851.2.
The market capitalization of the company is ₹420,483.45 crores.
The dividend yield represents the percentage of a company stock price paid out as dividends annually. For example, if the dividend yield is 0.94%, it means the company pays this percentage of its stock price as a dividend each year.
The P/E ratio is a measure of a company stock price relative to its earnings per share (EPS). For this stock, the current P/E ratio is 38.52.
The company operates in the Healthcare sector.
The current price of Sun Pharmaceutical Industries Limited is ₹1,752.50. If the stock takes a bullish turn, you can expect the target price to be around ₹1,840.13. On the other hand, if the market turns bearish, the target price could drop to approximately ₹1,664.88.
The company, Sun Pharmaceutical Industries Limited (ISIN: INE044A01036), is a leading player in the Drug Manufacturers - Specialty & Generic sector in India. With a market capitalization of ₹420,483.45 crores and an average daily trading volume of 2,334,600 shares, it is actively engaged in the Drug Manufacturers - Specialty & Generic industry. The company recently declared a dividend of 16.5."